354 trials (keyword fallback)
Cerebral Vein Thrombosis · Deep Vein Thrombosis · Gonadal Thrombosis
Primary: 6 Month Bleeding Rate — 0; 2.1 percentage of patients
Jugular Venous Flow
Primary: Internal Jugular Venous Flow — 0.04; 0.4; 0.04; 0.21 cm2
Venous Thromboembolism · Venous Thrombosis
Primary: Number of Patients With Asymptomatic Venous Thrombosis of Lower Limbs as Detected by Duplex Ultrasound — 1; 34 Participants — p=<0.001
Venous Thromboembolism
Primary: Number of Participants With Postoperative VTE Within 48 Hours After Surgery — 5; 3 participants — p=0.72
Venous Thromboembolism · Deep Vein Thrombosis · Pulmonary Embolus
Primary: Number of Participants With Venous Thromboembolism Events — 1 Participants
Venous Thromboembolism
Primary: Percentage of Participants With At Least 1 Symptomatic Venous Thromboembolism Recurrence - Overall — 3.8 Percentage of VTE recurrence
Intravenous Access
Primary: First Attempt Success Rate — 17; 11 Participants
Varicose Ulcer
Primary: Identification of Biomarkers Predictive of Ulcer Healing. — 9 Number of biomarkers
Embolism, Pulmonary
Primary: The Percentage of Participants With Recurrent or New Symptomatic Venous Thromboembolism (VTE) — 0; 0 percentage of participants
Upper Extremity Deep Vein Thrombosis · Central Venous Catheter Thrombosis · Cancer
Primary: Primary Feasibility Outcome - Number of Participants Recruited Per Month — 7.5; 2.0 Average enrolment rate/month/site
Venous Thromboembolism
Primary: Number of Participants Who Continued Treatment With Apixaban or Warfarin Following Discharge From the Hospital — 11966; 1979 Participants
Venous Thromboembolism · Thromboembolism · Thrombosis
Primary: Percentage of Subjects With Venous Thromboembolism Events — 3.8; 2.8; 4.1 percent of participants with VTE event
Thromboembolism · Venous Thromboembolism
Primary: Number of Participants Receiving Fondaparinux in the Indicated Therapy Intervals — 6; 0; 1; 3 participants
Arthroplasty, Replacement, Knee · Venous Thrombosis
Primary: Percentage of Participants Who Have a Composite Endpoint Consisting of Total Venous Thromboembolic Event (VTE) and All Cause Mortality During the Treatment Period…
Neoplasms
Primary: Percentage of Participants With Time to First Occurrence of Primary Efficacy Endpoint (Composite and Components) — 8.79; 5.95; 1.90; 2.14 Percentage of participants…